TY - JOUR
T1 - Target selection for deep brain stimulation in treatment resistant schizophrenia
AU - Corripio, Iluminada
AU - Roldán, Alexandra
AU - McKenna, Peter
AU - Sarró, Salvador
AU - Alonso-Solís, Anna
AU - Salgado, Laura
AU - Álvarez, Enric
AU - Molet, Joan
AU - Pomarol-Clotet, Edith
AU - Portella, Maria
N1 - Publisher Copyright:
© 2021
PY - 2022/1/10
Y1 - 2022/1/10
N2 - The use of deep brain stimulation (DBS) in treatment resistant patients with schizophrenia is of considerable current interest, but where to site the electrodes is challenging. This article reviews rationales for electrode placement in schizophrenia based on evidence for localized brain abnormality in the disorder and the targets that have been proposed and employed to date. The nucleus accumbens and the subgenual anterior cingulate cortex are of interest on the grounds that they are sites of potential pathologically increased brain activity in schizophrenia and so susceptible to the local inhibitory effects of DBS; both sites have been employed in trials of DBS in schizophrenia. Based on other lines of reasoning, the ventral tegmental area, the substantia nigra pars reticulata and the habenula have also been proposed and in some cases employed. The dorsolateral prefrontal cortex has not been suggested, probably reflecting evidence that it is underactive rather than overactive in schizophrenia. The hippocampus is also of theoretical interest but there is no clear functional imaging evidence that it shows overactivity in schizophrenia. On current evidence, the nucleus accumbens may represent the strongest candidate for DBS electrode placement in schizophrenia, with the substantia nigra pars reticulata also showing promise in a single case report; the ventral tegmental area is also of potential interest, though it remains untried.
AB - The use of deep brain stimulation (DBS) in treatment resistant patients with schizophrenia is of considerable current interest, but where to site the electrodes is challenging. This article reviews rationales for electrode placement in schizophrenia based on evidence for localized brain abnormality in the disorder and the targets that have been proposed and employed to date. The nucleus accumbens and the subgenual anterior cingulate cortex are of interest on the grounds that they are sites of potential pathologically increased brain activity in schizophrenia and so susceptible to the local inhibitory effects of DBS; both sites have been employed in trials of DBS in schizophrenia. Based on other lines of reasoning, the ventral tegmental area, the substantia nigra pars reticulata and the habenula have also been proposed and in some cases employed. The dorsolateral prefrontal cortex has not been suggested, probably reflecting evidence that it is underactive rather than overactive in schizophrenia. The hippocampus is also of theoretical interest but there is no clear functional imaging evidence that it shows overactivity in schizophrenia. On current evidence, the nucleus accumbens may represent the strongest candidate for DBS electrode placement in schizophrenia, with the substantia nigra pars reticulata also showing promise in a single case report; the ventral tegmental area is also of potential interest, though it remains untried.
KW - DBS
KW - Deep brain stimulation
KW - Habenula nucleus
KW - Nucleus accumbens
KW - Schizophrenia
KW - Subgenual anterior cingulate cortex
KW - Substantia nigra pars reticulata
KW - DBS
KW - Deep brain stimulation
KW - Habenula nucleus
KW - Nucleus accumbens
KW - Schizophrenia
KW - Subgenual anterior cingulate cortex
KW - Substantia nigra pars reticulata
KW - DBS
KW - Deep brain stimulation
KW - Habenula nucleus
KW - Nucleus accumbens
KW - Schizophrenia
KW - Subgenual anterior cingulate cortex
KW - Substantia nigra pars reticulata
UR - http://www.scopus.com/inward/record.url?scp=85114953817&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2021.110436
DO - 10.1016/j.pnpbp.2021.110436
M3 - Article
C2 - 34517055
AN - SCOPUS:85114953817
SN - 0278-5846
VL - 112
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
M1 - 110436
ER -